Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole SIE vs Femara with ribociclib in HR-positive/HER2-negative advanced breast cancer
2025-524846-85-00Phase 3Authorised
- Sponsor
- Laboratorios Farmacéuticos ROVI
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of letrozole and ribociclib in breast cancer (2 arms), sponsored by Laboratorios Farmacéuticos ROVI. Primary endpoint: Progression-free survival. Planned start Aug 2026; status: authorised.
02
Drugs
letrozoleribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-524846-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524846-85-00.